Kaleido Biosciences Stock Cash Per Share
| KLDODelisted Stock | USD 0.01 0.00 0.00% |
Kaleido Biosciences fundamentals help investors to digest information that contributes to Kaleido Biosciences' financial success or failures. It also enables traders to predict the movement of Kaleido Pink Sheet. The fundamental analysis module provides a way to measure Kaleido Biosciences' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Kaleido Biosciences pink sheet.
Kaleido |
Kaleido Biosciences Company Cash Per Share Analysis
Kaleido Biosciences' Cash per Share is a ratio of current cash on hands or in the banks of the company to a total number of shares outstanding. It is used to determine a firm's liquidity and is a good indicator of the overall financial health of a company. Value investors often compare this ratio to the current stock quote, and if it exceeds the stock price they would invest in it.
Current Kaleido Biosciences Cash Per Share | 0.90 X |
Most of Kaleido Biosciences' fundamental indicators, such as Cash Per Share, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Kaleido Biosciences is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Companies with high Cash per Share ratio will be considered as an attractive investment by most investors. In most industries if you can single out an equity instrument trading below its cash per share value, you have a bargain and should consider buying it. Finding the stocks traded below their cash value, therefore, can be a good starting point for investors using strategies based on fundamentals.
CompetitionIn accordance with the recently published financial statements, Kaleido Biosciences has a Cash Per Share of 0.9 times. This is 79.31% lower than that of the Pharmaceuticals sector and 79.21% lower than that of the Health Care industry. The cash per share for all United States stocks is 82.04% higher than that of the company.
Kaleido Cash Per Share Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Kaleido Biosciences' direct or indirect competition against its Cash Per Share to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Kaleido Biosciences could also be used in its relative valuation, which is a method of valuing Kaleido Biosciences by comparing valuation metrics of similar companies.Kaleido Biosciences is currently under evaluation in cash per share category among its peers.
Kaleido Fundamentals
| Return On Equity | -5.81 | ||||
| Return On Asset | -1.0 | ||||
| Operating Margin | (79.28) % | ||||
| Current Valuation | (16.73 M) | ||||
| Shares Outstanding | 42.62 M | ||||
| Shares Owned By Insiders | 0.73 % | ||||
| Shares Owned By Institutions | 0.36 % | ||||
| Number Of Shares Shorted | 2.34 M | ||||
| Price To Earning | (1.45) X | ||||
| Price To Book | 0 X | ||||
| Price To Sales | 0.04 X | ||||
| Revenue | 1.1 M | ||||
| Gross Profit | (66.7 M) | ||||
| EBITDA | (85.09 M) | ||||
| Net Income | (90.29 M) | ||||
| Cash And Equivalents | 38.47 M | ||||
| Cash Per Share | 0.90 X | ||||
| Total Debt | 5.55 M | ||||
| Debt To Equity | 2.04 % | ||||
| Current Ratio | 1.42 X | ||||
| Book Value Per Share | 0.25 X | ||||
| Cash Flow From Operations | (77.09 M) | ||||
| Short Ratio | 29.34 X | ||||
| Earnings Per Share | (2.16) X | ||||
| Target Price | 22.0 | ||||
| Number Of Employees | 76 | ||||
| Beta | 0.42 | ||||
| Market Capitalization | 421.96 K | ||||
| Total Asset | 50.14 M | ||||
| Retained Earnings | (197.63 M) | ||||
| Working Capital | 62.54 M | ||||
| Current Asset | 72.93 M | ||||
| Current Liabilities | 10.39 M | ||||
| Z Score | -6.3 | ||||
| Net Asset | 50.14 M |
About Kaleido Biosciences Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Kaleido Biosciences's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Kaleido Biosciences using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Kaleido Biosciences based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in unemployment. You can also try the Fundamentals Comparison module to compare fundamentals across multiple equities to find investing opportunities.
Other Consideration for investing in Kaleido Pink Sheet
If you are still planning to invest in Kaleido Biosciences check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Kaleido Biosciences' history and understand the potential risks before investing.
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities | |
| Portfolio Rebalancing Analyze risk-adjusted returns against different time horizons to find asset-allocation targets | |
| CEOs Directory Screen CEOs from public companies around the world | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Portfolio Volatility Check portfolio volatility and analyze historical return density to properly model market risk | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk |